Article, News
Prescient (ASX:PTX) reports promising clinical data for PTX-100 in relapsed and refractory TCL – Kalkine Media
Prescient Therapeutics Limited (ASX:PTX) has shared an encouraging update for the ongoing clinical trial of its PTX-100 compound in patients with relapsed and refractory T…
Article, News
PTX receives expanded Orphan Drug Designation for all T-cell lymphomas
Clinical stage oncology company, Prescient Therapeutics (ASX: PTX), has received an expanded Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for its…
Article, News
Prescient Therapeutics (ASX:PTX) lands FDA Orphan Drug status for PTX-100, shares soar – Kalkine Media
Australia’s clinical-stage oncology company Prescient Therapeutics (ASX: PTX) — developing targeted therapies (PTX-100 and PTX-200) and cellular therapies (OmniCAR, CellPryme-M, and CellPryme-A) — has received…
Article, News
Prescient Therapeutics thrilled with additional Orphan Drug Designation status for PTX-100
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including…
Article, News
FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
Clinical state oncology company Prescient Therapeutics (ASX: PTX) has received the US FDA’s Orphan Drug Designation for its PTX-100 drug, used for cancer treatment. Previously,…
Article, News
Prescient Therapeutics granted US FDA additional Orphan Drug Designation for PTX-100; shares up
Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including cutaneous…
Article, News
FDA grants Prescient Therapeutics (ASX:PTX) broad orphan drug status for PTX-100 cancer treatment
Oncology company Prescient Therapeutics (PTX) has been granted broad orphan drug designation (ODD) for its PTX-100 drug by the US Food and Drug Administration (FDA)….
Article, News
Prescient Therapeutics granted US FDA additional Orphan Drug Designation for PTX-100; shares up
Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including cutaneous TCL (CTCL)….
Article, News
Prescient’s PTX-100 granted FDA’s Orphan Drug Designation for all T-cell lymphomas
The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of 7 years. The US FDA has just granted Prescient Therapeutics (ASX:PTX)’s…
Article, News
Prescient Therapeutics receives FDA orphan drug status for PTX-100 to treat T-cell lymphomas
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has secured an orphan drug designation from the US Food and Drug Administration (FDA) for its lead candidate PTX-100…